Cytokinetics Rocked By Another Omecamtiv Setback
But Hope Remains For Subpopulation
The biotech’s cardiology asset has failed an advanced study focused on exercise capacity in heart failure, having underwhelmed observers with past data, but hope remains that the LVEF subset could be a saving grace.
